Search

Displaying results 4691 - 4700 of 5923 in total
  1. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    second messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and these diverse cellular effects have implicated deficiencies in its production (primarily due

    Categories: P-glycoprotein substrates
  2. Drug

    Vitex agnus-castus fruit extract

    go.drugbank.com/drugs/DB13193
    Investigational

    main mechanism of action of vitex agnus-castus fruit extract has not been fully elucidated, however it is suggested to modulate the stress-induced prolactin secretion via dopaminergic actions, and μ (mu

  3. Drug

    Horse chestnut

    go.drugbank.com/drugs/DB13195
    Investigational

    Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of bleeding due to anticoagulant actions.

  4. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication.

  6. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]

  7. Drug

    Lasmiditan

    go.drugbank.com/drugs/DB11732
    ApprovedInvestigational

    [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016].

  9. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada.

  10. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    Although corticosteroids effectively slow disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors